Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 4 of 4 publications.

Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24

Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774

Donnelly DW, Hegarty A, Sharp L, Carsin AE, Deady S, McCluskey N, Comber H, Gavin A. The impact of adjustment for socioeconomic status on comparisons of cancer incidence between two European countries. J Cancer Epidemiol. 2013 Jan 1;2013:612514. doi: 10.1155/2013/612514

Kovac AL, Pearman MH, Khalil SN, Scuderi PE, Joslyn AF, Prillaman BA, Cox F. Ondansetron prevents postoperative emesis in male outpatients.S3A-379 study group. J Clin Anesth. 1996 Dec;8(8):644-51. doi: 10.1016/s0952-8180(96)00173-0